RxDoctor Payments Data

Michelie Levrier

Psychiatric/Mental Health · Saint Cloud, FLNPI 1669945747

Payments from drug & device makers

$8,025in general payments, 2019–2025

Across 471 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alkermes, Inc.$2K
  • Supernus Pharmaceuticals, Inc.$788
  • Axsome Therapeutics, Inc.$680
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$619
  • Otsuka America Pharmaceutical, Inc.$545
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$7,96199%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,025 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$55,431
Medicare patients
55
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole31$56,921
VraylarCariprazine Hcl24$39,255
Abilify MaintenaAripiprazole11$26,493
LybalviOlanzapine/Samidorphan Malate11$21,614
Lamotrigine ErLamotrigine25$5,103
Lurasidone Hcl19$4,921
Aripiprazole37$1,818
Bupropion XlBupropion Hcl55$1,243
Trazodone Hcl72$1,243
Duloxetine Hcl39$1,188
Quetiapine Fumarate59$992
Mirtazapine26$886
Lamotrigine83$750
Clonazepam114$692
Buspirone Hcl77$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$545$83,41442 claims
AbbVieVraylar$2,316$39,25524 claims
Alkermes, Inc.Lybalvi$1,512$21,61411 claims
Almatica Pharma LLCSertraline Hcl$19$47877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Saint Cloud

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →